Novartis buys remaining rights to GSK treatment in deal up to US$1b
[ZURICH] Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline.
Basel-based Novartis will make an initial upfront payment of US$300 million to GSK for the acquisition of the compound and a further US$200 million payable following the start of a phase III study in MS by Novartis.
Payments of up to US$534 million may be made if pre-agreed milestones are met, Novartis said in a statement.
Novartis will also pay royalties of up to 12 percent to GSK on any future net sales of Ofatumumab in autoimmune conditions.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO